Sodium Dichloroacetate

Drug Overview

Sodium dichloroacetate (DCA) is a small molecule compound that has been used in medicine for decades. Historically, it was used primarily to treat rare metabolic disorders in children. However, it has gained significant attention in modern oncology as a potential “Smart Drug” because of its unique ability to target the specific ways cancer cells create energy.

Unlike traditional chemotherapy that kills all fast-growing cells, sodium dichloroacetate is being studied for its ability to “reset” the internal machinery of a tumor. By changing the cell’s metabolism, it aims to make cancer cells more susceptible to natural cell death.

• Generic name: Sodium dichloroacetate
• US Brand names: None (Currently available as a pharmaceutical-grade chemical or through clinical trials)
• Drug Class: Pyruvate Dehydrogenase Kinase (PDK) Inhibitor
• Route of Administration: Oral (powder or capsules) or Intravenous (IV)
• FDA Approval Status: Investigational for oncology; used as an “orphan drug” for metabolic conditions.

What Is It and How Does It Work? (Mechanism of Action)

Sodium dichloroacetate is a premier example of “Metabolic Therapy.” To understand how it works at the molecular level, we have to look at how cancer cells breathe and eat.

Most healthy cells use their “power plants,” called mitochondria, to burn sugar for energy using oxygen. In contrast, cancer cells often switch to a less efficient process called “aerobic glycolysis,” even when oxygen is available. This is known as the Warburg Effect. Cancer cells shut down their mitochondria to avoid “apoptosis,” which is the programmed cell death that usually happens when a cell’s power plant detects damage.

Sodium dichloroacetate works by targeting an enzyme called Pyruvate Dehydrogenase Kinase (PDK).

1. Inhibiting the Switch: In a tumor, PDK acts like a lock that keeps the mitochondria turned off. Sodium dichloroacetate binds to and inhibits PDK.
2. Re-activating the Power Plant: Once the PDK “lock” is removed, an enzyme called Pyruvate Dehydrogenase (PDH) is activated. This forces the cancer cell to start using its mitochondria again to process sugar.
3. Restoring Cell Death Signals: When the mitochondria are turned back on, they begin to produce reactive oxygen species and leak “pro-death” signals into the cell. This reactivates the signaling pathways for apoptosis.
4. Starving the Tumor: By forcing the cell back into normal metabolism, the drug also reduces the amount of lactic acid the tumor produces. Lactic acid usually helps the tumor invade nearby tissues and hide from the immune system.

FDA Approved Clinical Indications

Currently, sodium dichloroacetate is not FDA-approved as a primary treatment for cancer. It is recognized as an investigational agent in oncology and is used under “compassionate use” or in clinical trials.

Oncological uses

• Investigational treatment for advanced solid tumors (including glioblastoma, breast, and lung cancer).
• Investigational treatment for metastatic head and neck squamous cell carcinoma.
• Research into its use as a “sensitizer” to make radiotherapy and chemotherapy more effective.

Non-oncological

• Treatment of congenital lactic acidosis (a rare metabolic disease in children).
• Management of certain mitochondrial diseases.

Dosage and Administration Protocols

Dosing for sodium dichloroacetate in cancer patients is typically calculated based on body weight. Because the drug can build up in the system, many doctors use “cycle” dosing.

Dose Adjustments

If a patient has hepatic (liver) insufficiency, the drug must be used with extreme caution as the liver is responsible for breaking it down. For patients with a specific genetic variation (the GSTZ1 gene), the drug may stay in the body much longer, requiring a significantly lower dose or a “5 days on, 2 days off” schedule to prevent nerve damage.

Clinical Efficacy and Research Results

Clinical research data from 2020 to 2025 has moved toward using sodium dichloroacetate in combination with other therapies.

In small-scale Phase 1 and 2 trials, numerical data show that DCA is active in tumors like Glioblastoma (a type of brain cancer). In some studies, patients receiving DCA alongside standard care showed a stabilization of the disease for several months. For example, some case series reported a “clinical benefit rate” where approximately 50 percent of patients with advanced, treatment-resistant cancers saw their tumors stop growing for a period of time. However, large-scale Phase 3 trials are still needed to confirm these survival rates. Researchers are currently focusing on the “synergistic” effect, where DCA makes tumors 20 to 30 percent more sensitive to radiation therapy in laboratory models.

Safety Profile and Side Effects

Black Box Warning

Sodium dichloroacetate does not have an official Black Box Warning, but it carries a strong warning regarding “Peripheral Neuropathy,” which is damage to the nerves in the hands and feet.

Common side effects

These occur in more than 10 percent of patients, especially at higher doses:

• Tingling or numbness in fingers and toes (neuropathy)
• Digestive upset (nausea or heartburn)
• Drowsiness or “mental fog”
• Tremors or shaky hands

Serious adverse events

• Severe Peripheral Neuropathy: This can lead to weakness in the legs and trouble walking if the dose is not lowered.
• Reversible Liver Stress: Indicated by a rise in liver enzymes.
• Confusion or Hallucinations: Occurring more often in elderly patients or those taking other brain-acting medications.

Management strategies

The most important strategy is “start low and go slow.” Many doctors prescribe Vitamin B1 (thiamine), Alpha Lipoic Acid, and Acetyl-L-Carnitine alongside DCA, as these supplements may help protect the nerves from damage. If numbness or tingling begins, the dose should be reduced or stopped until symptoms disappear.

Research Areas

Sodium dichloroacetate is a major focus in Research Areas involving the “Tumor Microenvironment.” Scientists are studying if reducing the acidity of a tumor with DCA can help modern Immunotherapy (like T-cell therapy) work better. Additionally, there is interest in the field of regenerative medicine regarding how DCA might influence healthy stem cells. Early research suggests that while DCA forces cancer cells to die, it might actually help protect healthy heart and brain cells from damage caused by low oxygen or chemotherapy.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Blood tests for liver function (ALT, AST).
• A baseline neurological exam to check for existing nerve damage.
• Genetic testing for the GSTZ1 gene (if available) to determine how fast your body processes the drug.

Precautions during treatment

Patients must be monitored for “gait changes” (changes in how they walk). If you feel like you are becoming clumsy or stumbling, it is a sign of nerve stress.

Do’s and Don’ts list

• Do take the medication with food to protect your stomach.
• Do take nerve-supporting supplements like Vitamin B1 if your doctor recommends them.
• Do report any “pins and needles” sensations in your hands or feet right away.
• Don’t drink alcohol while taking DCA, as it can increase the risk of liver stress and nerve damage.
• Don’t take extra doses to “speed up” the process; the drug takes time to change cell metabolism.
• Don’t ignore signs of extreme sleepiness or confusion.

Legal Disclaimer

The information in this guide is for educational purposes only and does not constitute medical advice. Sodium dichloroacetate is an investigational drug in the field of oncology and has not been approved by the FDA for the treatment of cancer. Always consult with a qualified oncologist or healthcare professional before starting any new treatment or participating in a clinical trial.